Mitomycin medac

DRUG2 trials

Sponsors

Region Skane, Region Skane, Turku University Hospital

Conditions

Bladder cancerPrimary or recurrent non-muscle invasive bladder cancer with intermediate risk of recurrence after transurethral tumour resection

Phase 3

Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial)

Active, not recruitingCTIS2023-504945-30-00

Region Skane, Region SkanePrimary or recurrent non-muscle invasive bladder cancer with intermediate risk of recurrence after transurethral tumour resection

Start: 2021-03-16Target: 340Updated: 2024-08-30

Intravesical instillation therapy with bacillus Calmette-Guérin (BCG) and sequential BCG and electromotive mitomycin-C (EMDA-MMC) in patients with high-risk non-muscle-invasive bladder carcinoma (FINNBLADDER 10)

RecruitingCTIS2024-516320-33-00

Turku University HospitalBladder cancer

Start: 2019-01-07Target: 300Updated: 2024-09-19